Uncategorized

Hitting your target selectively. The potential of EIRNA Bio’s c-MAST Screening platform to rapidly identify off-target effects.

Hitting your target selectively. The potential of EIRNA Bio’s c-MAST Screening platform to rapidly identify off-target effects.

In the realm of drug discovery, understanding the mechanism of action of therapeutic compounds is crucial, and ribosome profiling (Ribo-seq) has emerged as a powerful tool for this purpose. Despite its strengths, the application of Ribo-seq in a high-throughput manner poses practical limitations. The resource-intensive nature of the technology makes it challenging to triage large

Hitting your target selectively. The potential of EIRNA Bio’s c-MAST Screening platform to rapidly identify off-target effects. Read More »

Assessing Selectivity of Premature Termination Codon Therapeutic Approaches Using Ribosome Profiling

By Gary Loughran, Head of Biology Introduction Mutations that introduce a premature termination codon (PTC) into the mRNA lead to the synthesis of truncated and usually non-functional proteins that may cause disease. Furthermore, mRNA surveillance pathways, such as the nonsense-mediated mRNA decay (NMD) pathway, can compound the impact of PTCs by degrading mutant mRNAs to

Assessing Selectivity of Premature Termination Codon Therapeutic Approaches Using Ribosome Profiling Read More »

Revolutionizing Gene Annotation: The Power of Ribosome Profiling

By Gary Loughran, Head of Biology Gene annotation is a cornerstone of genomics, providing insights into the functional elements of the genome and enabling researchers to understand the roles of genes in health, disease, and development. However, due to the complexity of many genomes, gene annotation is a daunting task, and traditional methods often fall

Revolutionizing Gene Annotation: The Power of Ribosome Profiling Read More »

Scroll to Top